舒血宁注射液对COPD伴发抑郁障碍患者认知功能的影响  

Effects of Shuxuening parenteral solution on cognition function in patients with chronic obstructive pulmonary disease complicated with depression

作　　者：郑加辉[1] 万国仕[1] 郑元秀[1] 黄芳芳[1] 王珠美[1] ZHENG Jia-hui WAN Guo-shi ZHENG Yuan-xiu HUANG Fang-fang WANG Zhu-mei(Yuhang District Second People＇s Hospital of Hangzhou City, Hangzhou 311121, China)

机构地区：[1]杭州市余杭区第二人民医院,杭州311121

出　　处：《实用药物与临床》2017年第10期1177-1180,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的观察舒血宁注射液对COPD伴发抑郁障碍患者认知功能的影响。方法78例COPD合并抑郁障碍的患者随机分成2组:治疗组37例,对照组41例。对照组给予COPD常规治疗;治疗组在对照组基础上给予舒血宁注射液15 mL稀释后静脉滴注,2次/d,疗程均为15 d。采用HAMD24抑郁量表评定患者抑郁障碍,采用MoCA量表评定患者整体认知功能水平,采用COPD评估测试问卷评定患者生活质量。观察治疗前后患者肺功能、生活质量及抑郁障碍、认知功能水平变化情况。结果最终共73例患者完成了本研究,其中治疗组34例,对照组39例。治疗前,两组患者肺功能各项指标、HAMD评分、MoCA评分及CAT问卷评分比较差异均无统计学意义(P>0.05);治疗后,治疗组肺功能指标(FVC、FEV1、FEV1占预计值%、FEV1/FVC%)及MoCA评分较治疗前和对照组显著升高(P<0.01,P<0.05),HAMD评分及CAT问卷评分较治疗前和对照组显著下降(P<0.05)。Spearman相关性检验发现,HAMD评分与FEV1占预计值%、FEV1/FVC%呈明显负相关(r=-0.686、-0.732,P<0.01),与CAT问卷评分呈明显正相关(r=0.794,P<0.01);MoCA评分与FEV1占预计值%、FEV1/FVC%呈明显正相关(r=0.707、0.682,P<0.01),与CAT问卷评分呈明显负相关(r=-0.663,P<0.01)。结论舒血宁注射液能在一定程度上改善COPD伴发抑郁障碍患者的抑郁状况及认知功能,并能改善其肺功能及生活质量。Objective To investigate the effects of Shuxuening parenteral solution on cognition function in patients w ith chronic obstructive pulmonary disease（ COPD） complicated w ith depression. Methods Totally 78 patients w ith COPD complicated w ith depression w ere randomly divided into treatment group（ n = 37） and control group（ n =41）. Control group w as given conventional therapy,and experiment group w as given Shuxuening parenteral solution,15 m L being diluted for intravenous infusion,in addition to routine treatment,tw ice daily,and the course of treatment w as15 d. The depression disorder w as assessed w ith 24-item HAM D scale. The level of cognition w as assessed w ith M o CA scale. The quality of life in patients w as assessed w ith CAT questionnaire. The lung function,the scores of HAM D,M oCA and CAT questionnaire w ere investigated before and after treatment. Results Totally 73 patients completed the study（ 34 cases in experiment group,and 39 cases in control group）. There w as no significant difference in the lung function,the scores of HAM D,M o CA and CAT questionnaire betw een the tw o groups before treatment（ P〈0. 05）.After treatment,the lung function（ FVC,FEV1,FEV1/FVC% and FEV1 predicted） and the score of M o CA of patients in treatment group w ere significantly increased,and they w ere higher that those of control group（ P〈0. 05）; the scores of HAM D and CAT questionnaire w ere decreased significantly（ P〈0. 05）. The Spearman correlation test show ed thatthe HAM D score w as negatively correlated w ith FEV1 predicted and FEV1/FVC%（ r =-0. 686,-0. 732,P〈0. 01）,and positively correlated w ith CAT scores（ r = 0. 794,P〈0. 01）. The M o CA score w as positively correlated w ith FEV1 predicted% and FEV1/FVC %（ r = 0. 707,0. 682,P〈0. 01）,and negatively correlated w ith CAT questionnaire score（ r =-0. 663,P〈0. 01）. Conclusion Shuxuening parenteral solution can improve cognition function,lung function and quality of life in patients w ith COPD comp

关 键 词：舒血宁注射液 慢性阻塞性肺疾病 抑郁 认知功能 

分 类 号：R563.9[医药卫生—呼吸系统] R749.4[医药卫生—内科学]